Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | group enriched outside the brain (cone photoreceptor cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: mavacamten, danicamtiv, omecamtiv mecarbil | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 84 | 0.91 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 15362
Sealed predictions
- MYL4 in dopamine neurons, braak+0.18 (p 0.639) → -0.40 (p 0.291)receipt 15369
Swarm cases
receipt 15369: MYL4 in dopamine neurons, braak
- power
- full sample -0.08 (p 0.748, n 18), 95% CI -0.53 to +0.40. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.13 (p 0.615, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.11 (p 0.671, n 18). could be the mix.
- skeptic
- leave-one-out range -0.21 to +0.03, sign flips 4; without severely affected donors -0.08 (p 0.748, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MYL4 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts